CAMBRIDGE, Mass.--(BUSINESS WIRE)--Altus Pharmaceuticals Inc. (NASDAQ: ALTU), a biopharmaceutical company focused on oral and injectable protein therapeutics for patients with gastrointestinal and metabolic disorders, announced today that it has completed the previously announced underwritten public offering of 6,000,000 shares of its common stock at a public offering price of $14.75 per share. The aggregate gross proceeds from the offering were approximately $88.5 million before deducting underwriting discounts and commissions and offering expenses. Altus Pharmaceuticals has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock to cover over-allotments, if any. All of the shares were offered by Altus Pharmaceuticals. Merrill Lynch & Co. and Morgan Stanley & Co. were joint book-running managers for the offering. Cowen and Company and Leerink Swann & Company were co-managers for the offering.
